Skip to main content

Table 3 Prevalence data (%) based on HUNT3 questionnaires (Q1 or Q2) and general practitioner diagnoses (GPD)

From: The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms

 

Women age groups

Men age groups

 

20-39

40-59

60-79

80 +

20-39

40-59

60-79

80 +

Heart burn

Q2: A lot of heart burn

6.1

7.9

6.3

6.2

4.9

6.3

8.6

7.9

GPD: Heart burn or reflux (D03/D84)

3.9

8.2

10.0

11.0

2.5

7.6

12.1

12.0

Cardiovascular diseases

Q1: Angina pectoris

0.3

1.5

9.6

21.4

0.2

0.7

4.4

15.5

GPD: Angina pectoris (K74)

0.1

2.2

13.9

26.4

0

0.8

6.8

21.1

Q1: Myocardial infarction

0.1

2.3

10.1

21.2

0.0

0.5

3.0

8.6

GPD: Myocardial infarction (K75or K76)

1.0

3.3

12.9

18.8

0.5

1.3

4.7

10.4

Q1: Cerebral insult

0.6

1.5

5.4

11.6

0.3

1.1

3.9

8.6

GPD: Cerebral insult (K90 + 91)

0.4

2.2

7.3

17.0

0.4

1.4

5.7

14.2

Q1: Arterial hypertension

1.2

14.7

38.1

44.1

2.1

12.7

36.9

49.8

GPD: Arterial hypertension (K86 or K87)

2.7

14.7

37.4

42.2

2.2

12.9

37.1

49.4

NorPD: Drugs arterial hyper-tension (C02-03, 07–09)

1.7

16.0

51.5

70.3

2.2

15.7

49.5

67.7

Inflammatory and musculoskeletal diseases

Q1: Spondylarthritis or

rheumatoid arthritis

1.5

4.1

5.3

6.0

1.9

4.7

7.2

8.8

GPD: Spondylarthritis or rheumatoid arthritis (L88)

1.5

3.4

4.5

5.6

1.5

4.7

7.9

8.7

Q1: Arthrosis

0.8

6.1

17.2

23.3

1.0

12.8

34.2

45.5

GPD: Arthrosis hip or knee (L 89 + 90 + 91)

1.7

7.5

21.5

29.8

1.7

10.2

33.6

43.4

Q1: Osteoporosis

0.1

0.3

1.2

3.1

0.3

1.9

11.1

20.6

GPD: Osteoporosis L95

0.2

0.6

1.5

2.9

0.2

1.4

10.8

22.7

Neurological diseases

Q1: Headache

37.0

34.3

18.7

10.7

56.9

47.7

26.8

16.6

GPD: Headache (N01)

10.8

9.9

7.9

6.1

18.6

16.5

12.6

11.0

Q1: Migraine

3.1

4.5

2.7

3.4

10.4

11.2

5.1

5.0

GPD: Migraine (N89)

3.8

4.4

2.6

1.5

9.5

11.6

7.1

2.4

NorPD: Use of migraine drugs (N02)

1.0

1.0

0.5

0.2

3.5

4.9

2.0

0.3

Q1: Epilepsy

1.5

1.2

1.2

1.9

1.3

1.4

0.7

1.4

GPD: Epilepsy (N88)

1.8

1.7

1.8

1.5

1.5

1.7

1.5

1.2

Mental diseases and insomnia

Q2: HADS anxiety score > 8#

11.9

11.7

7.2

8.2

18.4

17.4

15.6

13.2

GPD: Anxiety or feeling of anxiety (P 01 + 74 +79)

6.7

8.5

8.5

8.6

9.7

14.1

14.0

15.4

Q2: HADS depression score > 8#

6.4

9.4

11.7

18.8

6.2

8.3

9.8

16.3

GPD: Depression or feeling of depression (P 03 + 76)

11.0

18.1

16.0

11.1

19.6

31.3

28.0

21.7

Q2: Insomnia many evenings or mornings a week

11.6

13.8

16.2

15.4

13.1

21.3

25.8

25.3

GPD: Sleeping disorder (P06)

6.3

8.6

18.8

24.0

6.3

13.3

21.7

32.4

Q1: COPD or chronic bronch

1.0

2.0

5.6

5.4

1.5

2.7

4.6

4.2

GPD: COPD or chronic bronchitis (R95)

0.1

1.9

7.9

13.2

0.2

1.8

7.2

7.0

Q1: Asthma

10.5

9.3

9.4

7.2

12.4

9.4

10.4

8.6

GPD: Asthma (R96)

10.6

7.0

9.2

10.0

10.4

9.7

11.9

9.9

Q1: Use of asthma or copd drugs in the last 5 years

8.1

7.5

11.3

9.6

10.4

9.6

12.5

9.7

GP prescription asthma drugs in the last 5 year (R03)

7.4

8.7

15.1

17.4

9.8

11.4

17.3

12.6

NorPD: Use of asthma drugs in 2008 (R03)

4.6

5.6

11.6

14.2

5.7

7.7

13.0

9.1

Skin diseases

Q1: Psoriasis

4.1

6.8

7.0

3.8

3.3

6.2

6.6

4.1

GPD: Psoriasis (S91)

2.0

4.6

5.5

4.6

2.7

4.5

5.8

2.8

Endocrine disorders

Q1: Hyperthyreosis

0.3

0.7

1.3

2.5

1.4

2.6

3.4

3.2

GPD: Hyperthyreosis (T85)

0.2

0.5

0.7

0.7

0.6

1.9

2.0

2.0

Q1: Hypothyreosis

0.6

2.1

2.9

5.3

4.1

8.0

12.3

12.1

GPD: Hypothyreosis (T86)

1.4

1.9

4.2

6.7

3.2

7.8

12.7

13.8

GP prescription thyroid hormone (H03AA01)

0.5

1.5

3.3

5.1

2.2

7.0

12.1

12.5

NorPD: Use of thyroid hormone (H03AA01)

0.5

2.0

3.7

5.9

2.6

7.9

14.2

13.4

Q1: Diabetes mellitus

0.8

3.4

9.2

9.2

0.8

2.4

6.9

9.7

GPD: Diabetes mellitus (T89 + 90)

1.2

4.8

13.7

16.3

1.4

3.6

10.4

13.0

GP prescription antidiabetic drug (A10A or A10B)

0.8

4.0

10.9

10.9

1.2

2.8

7.9

8.8

NorPD: Antidiabetic drug (A10A or A10B)

1.1

4.1

11.1

11.7

1.5

2.6

8.4

9.2

Urinary tract

Q2: Urinary incontinence

4.7

7.6

10.4

13.1

22.2

27.5

27.4

32.8

GPD: Urinary incontinence (U04)

1.0

0.5

3.0

8.7

2.2

6.8

10.5

22.0

  1. HUNT data are restricted to the municipalities being represented by eight randomly selected general practices, and include 28 872 HUNT3 participants (57% of invited in these municipalities). Data from Norwegian Prescription Registry (NorPD) include the entire county for the year 2008.
  2. # Hospital Anxiety and Depression Scale (HADS) 14 items, cut-off 8 indicate minor, moderate and severe disease (REF).
  3. In parenthesis: For diagnosis – codes according to the International Classification of Primary Care (ICPC2), for medication codes according to The Anatomical Therapeutic Chemical Classification System (ATC).
Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us